Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 (Blarcamesine) in Pediatric Rett Syndrome
NCT04304482Phase 3Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of blarcamesine in Rett syndrome (RTT), sponsored by Anavex Life Sciences Corp.. Started Jul 2020; status: completed.
02
Drugs
blarcamesine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04304482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304482.